These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
455 related articles for article (PubMed ID: 19940755)
41. Nephrogenic systemic fibrosis, in patients with end-stage kidney disease on dialysis, in the greater Auckland region, from 2000-2006. Kendrick-Jones JC; Voss DM; De Zoysa JR Nephrology (Carlton); 2011 Feb; 16(2):243-8. PubMed ID: 21272139 [TBL] [Abstract][Full Text] [Related]
42. Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy: a primer for radiologists. Prasad SR; Jagirdar J J Comput Assist Tomogr; 2008; 32(1):1-3. PubMed ID: 18303280 [TBL] [Abstract][Full Text] [Related]
43. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark. Elmholdt TR; Pedersen M; Jørgensen B; Søndergaard K; Jensen JD; Ramsing M; Olesen AB Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765 [TBL] [Abstract][Full Text] [Related]
44. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Broome DR Eur J Radiol; 2008 May; 66(2):230-4. PubMed ID: 18372138 [TBL] [Abstract][Full Text] [Related]
45. Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis. Peak AS; Sheller A Ann Pharmacother; 2007 Sep; 41(9):1481-5. PubMed ID: 17684032 [TBL] [Abstract][Full Text] [Related]
54. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure. Grobner T; Prischl FC Semin Dial; 2008; 21(2):135-9. PubMed ID: 18226001 [TBL] [Abstract][Full Text] [Related]
55. Gadolinium-associated nephrogenic systemic fibrosis in patients with renal failure: the need for an interdisciplinary helping network. Stratta P; Canavese C; Quaglia M; Fenoglio R Rheumatology (Oxford); 2010 Apr; 49(4):821-3. PubMed ID: 20032228 [No Abstract] [Full Text] [Related]
56. Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis. Heverhagen JT; Krombach GA; Gizewski E Rofo; 2014 Jul; 186(7):661-9. PubMed ID: 24477507 [TBL] [Abstract][Full Text] [Related]
57. [Nephrogenic systemic fibrosis and gadolinium-based contrast media]. Andréjak M; Thuillier D; Lok C; Gras-Champel V Therapie; 2007; 62(2):169-72. PubMed ID: 17582319 [TBL] [Abstract][Full Text] [Related]
58. Nephrogenic systemic fibrosis developed after recovery from acute renal failure: gadolinium as a possible aetiological factor. Lu CF; Hsiao CH; Tjiu JW J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):339-40. PubMed ID: 18573157 [No Abstract] [Full Text] [Related]
59. Nephrogenic systemic fibrosis with septal panniculitis mimicking erythema nodosum. Naylor E; Hu S; Robinson-Bostom L J Am Acad Dermatol; 2008 Jan; 58(1):149-50. PubMed ID: 18158925 [TBL] [Abstract][Full Text] [Related]